New pill for Hard-to-Treat cancers shows early promise in small study
Disease control
Terminated
This early-stage study tested a new oral drug, ATX-559, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Accent Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC